Thymusaktive Eigenschaften des Mistellektin-1

Author(s): Ko, H., Tunggal, L., Uhlenbruck, G., Pulverer, G.

Abstract: The subcutaneous administration of the optimum immunomodulating dose of mistletoe lectin-1 (ML-1; 1 ng/kg body weight, twice a week) was accompanied in vivo 1. by a significant antimetastatic activity in two murine tumor models (BALB/c-mouse; L-1 sarcoma; RAW-lymphosarcoma) and 2. by a significant increase of defined acute phase proteine in tumor patients (e.g. C-reactive proteins, haptoglobin), the synthesis of which is regulated in the liver by cytokines (e.g. interleukin-6, interleukin- 1, tumor necrosis factor alpha). lt has already been demonstrated earlier, that a therapy with ML- 1 is accompanied by significant increases of certain lymphocyte subpopulations in the peripheral blood of tumor patients (e.g. helper T-lymphocytes, natural killer cells) as well as by a significantly increased activity status of the lymphatic cells of the peripheral blood (expression of interleukin-2 and HLA-DR-receptors). lt has been possible to demonstrate in vitro, that ML- 1 induces a significant interleukin-2 or HLA-DQ receptor expression as a correlate of the T and B lymphocyte activation and causes a strong cytokine release by mononuclear immune cells (e.g. interleukin-1 alpha, interleukin-2, interferon gamma and tumor necrosis factor alpha). In studies about the proliferation kinetics with murine and human tumor cell lines no proof was found for an increase by ML- 1.Within the scope of these examinations it was possible to clearly show the immunoactive and antimetastatical effect of ML- 1.

Keyword(s): Adjuvante Tumortherapie

Zurück | Weiter